142 related articles for article (PubMed ID: 31481511)
21. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Komrokji RS; Al Ali NH; Padron E; Cogle C; Tinsley S; Sallman D; Lancet JE; Lis AF
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):251-254. PubMed ID: 30852241
[TBL] [Abstract][Full Text] [Related]
22. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
23. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
24. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
25. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D
Clin Cancer Res; 2013 Jun; 19(12):3297-308. PubMed ID: 23596104
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
28. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
30. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
34. [Hematologic response predictor factors in adults with myelodysplastic syndromes (SMD) treated with cyclosporin A (CSA)].
Zamora-Pérez E; López-Karpovitch X
Gac Med Mex; 2015; 151(3):345-53. PubMed ID: 26089271
[TBL] [Abstract][Full Text] [Related]
35. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
37. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
[TBL] [Abstract][Full Text] [Related]
38. Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes.
Ghaderi A; Nodehi SRS; Bakhtiari T; Aslani M; Aghazadeh Z; Matsuo H; Rehm BHA; Cuzzocrea S; Mirshafiey A
J Clin Pharmacol; 2020 Jul; 60(7):879-888. PubMed ID: 32064621
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Abaza Y; Hidalgo-Lopez JE; Verstovsek S; Jabbour E; Ravandi F; Borthakur G; Estrov Z; Alvarado Y; Burger J; Schneider H; Soltysiak KA; Wei Y; Kantarjian HM; Bueso-Ramos CE; Garcia-Manero G
Leuk Res; 2018 Oct; 73():78-85. PubMed ID: 30245189
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T; Cadenas FL; Xicoy B; Alfonso-Pierola A; Platzbecker U; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D
Leuk Res; 2023 Nov; 134():107390. PubMed ID: 37776843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
